ArticleTumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine2016

A retrospective analysis of efficacy and safety of adding bevacizumab to chemotherapy as first- and second-line therapy in advanced non-small-cell lung cancer (NSCLC).

Rencui Quan et al.PubMed ↗Publisher ↗

No numbers read from the abstract.